Thursday, September 07, 2017 12:40:57 PM
Why? Dr. Simpson has repeatedly shown to be shareholder unfriendly.
She needs this reverse split to happen. If the shareholders reject it, again, maybe she takes the company into bankruptcy out of spite?
Nothing would happen to the patent. She'd line up DIP financing and would get the money she needs to resume operations, and there would be many lenders willing to provide that financing as it would supersede the noteholders. The shareholders who "screwed" her over by rejecting the reverse split would be the big losers, at least in her mind, so it would be a win-win.
Not to mention that she would probably keep her job and be issued new shares so she wouldn't end up losing out. She only has 40k or so shares right now, it's not like she has much to lose.
I don't think BK is likely either, but it's certainly an option that is on the table. If she truly is getting lowball offers, which I suspect she is right now because she has zero leverage, why wouldn't she want to file BK, try to restructure the debt, keep the company alive until FDA approval and negotiate a sale on her terms?
The only variable that would change is who the beneficiaries would be when the sale happens. Traditionally, old shareholders are wiped out and the creditors become the new shareholders. Do you really think Simpson cares if we are the ones to benefit from a sale or if it's the creditors?
My point was that if BK does happen, the shareholders' best chance of recovery is to try and force the courts to order a market test of the assets. If they exceed the value of the debt, either sell them and pay out the debt that way, or use it as leverage to renegotiate terms with the creditors (i.e. a partial debt for equity swap that leaves current shareholders only minimally diluted.
She needs this reverse split to happen. If the shareholders reject it, again, maybe she takes the company into bankruptcy out of spite?
Nothing would happen to the patent. She'd line up DIP financing and would get the money she needs to resume operations, and there would be many lenders willing to provide that financing as it would supersede the noteholders. The shareholders who "screwed" her over by rejecting the reverse split would be the big losers, at least in her mind, so it would be a win-win.
Not to mention that she would probably keep her job and be issued new shares so she wouldn't end up losing out. She only has 40k or so shares right now, it's not like she has much to lose.
I don't think BK is likely either, but it's certainly an option that is on the table. If she truly is getting lowball offers, which I suspect she is right now because she has zero leverage, why wouldn't she want to file BK, try to restructure the debt, keep the company alive until FDA approval and negotiate a sale on her terms?
The only variable that would change is who the beneficiaries would be when the sale happens. Traditionally, old shareholders are wiped out and the creditors become the new shareholders. Do you really think Simpson cares if we are the ones to benefit from a sale or if it's the creditors?
My point was that if BK does happen, the shareholders' best chance of recovery is to try and force the courts to order a market test of the assets. If they exceed the value of the debt, either sell them and pay out the debt that way, or use it as leverage to renegotiate terms with the creditors (i.e. a partial debt for equity swap that leaves current shareholders only minimally diluted.
Recent DCTH News
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
